PATIENT SELECTION FOR CIK THERAPY:
WHO IS A GOOD CANDIDATE?
A complete guide to the clinical factors that determine whether a patient is a good candidate for CIK cell therapy — and the criteria that require careful assessment before proceeding.
analyticsAt a Glance
- check_circleCIK therapy has broader eligibility than most advanced cell therapies — no donor matching, no genetic engineering
- check_circleKey selection factors: cancer type, ECOG performance status, lymphocyte count, and treatment context
- check_circlePatients with solid tumours, good immune reserve, and PS 0–2 are typically the strongest candidates
- check_circleCancerFax performs a structured case review to assess your individual eligibility before any commitment
Why CIK Has Broader Eligibility Than Most Cell Therapies
CIK therapy is more widely accessible than engineered cell therapies like CAR-T because it requires no genetic modification, no donor matching, and no highly specialised vector manufacturing. The result is a treatment whose eligibility is defined primarily by the patient's clinical condition and cancer context — not by a narrow antigen target or complex biosafety protocol.
“CIK therapy's broad eligibility is one of its greatest clinical strengths — it is not a therapy reserved for a narrow patient subset.”
No HLA Matching Required
Unlike allogeneic cell therapies, CIK uses the patient's own blood — eliminating the matching process that delays access to donor-dependent therapies. Any patient who can provide an adequate blood sample is a potential candidate from a manufacturing standpoint.
Applicable Across Tumour Types
CIK's MHC-unrestricted tumour killing is not limited to cancers expressing a specific antigen. Published evidence spans HCC, NSCLC, gastric, colorectal, NPC, renal cell, breast, and haematological cancers — making it relevant to a broad patient population.
CIK Therapy Eligibility — Complete Criteria Reference
A structured reference covering all the clinical factors assessed during patient selection for CIK therapy — from positive eligibility indicators to relative and absolute contraindications.
| Selection Factor | Favourable for CIK | Requires Assessment | Contraindicated |
|---|---|---|---|
| ECOG Performance Status | PS 0–1 | PS 2 (case-by-case) | PS 3–4 |
| Absolute Lymphocyte Count (ALC) | >1.0 × 10⁹/L | 0.5–1.0 × 10⁹/L (yield may be low) | <0.5 × 10⁹/L |
| Cancer type | Solid tumours (HCC, NSCLC, gastric, CRC, NPC) | Haematological malignancies | None based on type alone |
| Treatment context | Post-surgery, alongside chemo, post-TACE/RFA | During active intensive chemo (nadir) | During active HSCT (timing issue) |
| Autoimmune disease | None / well-controlled remission | Active / on high-dose immunosuppressants | Severe uncontrolled flare |
| Active infection | None | Mild/resolved infection | Active systemic infection / sepsis |
| Organ function | Adequate liver, renal, cardiac function | Child-Pugh B (HCC patients) | Child-Pugh C / severe organ failure |
| Systemic corticosteroids | None / physiological dose | Low-dose ongoing steroids | Immunosuppressive dose (>20mg/day prednisolone) |
| HIV status | HIV-negative | HIV+ with controlled viral load (case-by-case) | Advanced AIDS / CD4 <200 |
| Pregnancy | Not pregnant | — | Pregnancy (not studied; not recommended) |
The Ideal CIK Candidate Profile
While CIK therapy is applicable across a wide range of patients, certain clinical profiles represent the clearest candidates where evidence, biology, and practical feasibility align most strongly.
Post-Surgical Solid Tumour Patient
A patient who has undergone curative resection for HCC, gastric, colorectal, or NSCLC and has recovered adequate immune function — using CIK as adjuvant recurrence prevention. This is the best-evidenced, cleanest use case across the entire CIK literature.
Active Chemotherapy + CIK Combination
A patient receiving first- or second-line platinum-based or FOLFOX-based chemotherapy with ECOG PS 0–1, adequate ALC (>1.0), and a solid tumour type with published CIK combination evidence. CIK cells are collected between cycles.
Post-TACE or Post-RFA HCC Patient
A patient with HCC who has undergone TACE or RFA and is in a partial or complete response — using CIK as immune consolidation of the locoregional treatment effect. The most studied CIK combination paradigm in liver cancer.
Advanced Cancer on Stable Targeted Therapy
A patient with stable disease on sorafenib, lenvatinib, or another VEGFR inhibitor — adding CIK as an immune combination partner to target the residual disease that targeted therapy is controlling but not eliminating.
Good vs Poor Candidates — Clinical Signals
Recognising the clinical signals that identify strong CIK candidates — and those that suggest CIK is unlikely to be beneficial or feasible — helps patients and families have more productive conversations with their oncology team.
Good Candidate Signals
- ECOG PS 0–1 with preserved daily functionGood performance status predicts adequate immune reserve for effective CIK manufacturing and anti-tumour activity.
- Solid tumour with published CIK evidenceHCC, NSCLC, gastric, colorectal, NPC, or renal cancer — all have RCT data supporting CIK in at least one treatment context.
- Recent surgery, TACE, or RFA completedPost-locoregional treatment immune priming creates an ideal environment for CIK cell activity.
- ALC >1.0 and recovering from prior treatmentAdequate lymphocyte counts ensure sufficient PBMC input for a quality CIK manufacturing run.
Poor Candidate Signals
- ECOG PS 3–4 / bedridden / severe fatiguePoor performance status predicts inadequate immune reserve, low CIK manufacturing yield, and limited clinical benefit.
- Profound lymphopenia after intensive chemotherapyALC below 0.5 × 10⁹/L makes adequate CIK cell manufacturing unlikely — defer until immune recovery.
- Active uncontrolled systemic infectionActive infection compromises the quality and safety of CIK cell collection, manufacturing, and infusion.
- High-dose corticosteroid dependenceImmunosuppressive steroid doses suppress the T-cell populations that CIK therapy depends on for both manufacturing and clinical activity.
CIK Eligibility — Key Parameters
The core quantitative thresholds most commonly used in published CIK trials to define eligible patient populations.
- ECOG 0–2Performance status range in the majority of CIK trial inclusion criteriaMost published protocols enrol patients with PS 0–2 — PS 2 patients are generally included but may produce lower CIK cell yields.
- >1.0 × 10⁹/LMinimum absolute lymphocyte count for optimal CIK manufacturingPatients below this threshold may produce insufficient PBMC input for an effective CIK expansion run.
- No donor neededDonor matching or HLA typing requirement for CIK therapyAutologous cell sourcing eliminates the access barriers and waiting times associated with allogeneic cell therapies.
More from the CIK Cell Therapy Resource Library
Continue exploring CIK therapy — from side effects and costs to disease-specific evidence and the manufacturing process.
- CIK Cell Therapy — Complete Treatment Guide
- Side Effects of CIK Therapy: What Patients Experience
- Cost of CIK Therapy in China: A Complete Breakdown
- What Is CIK Therapy? A Complete Patient Introduction
- How CIK Cells Are Made: The Manufacturing Process
- CIK Therapy at Chinese Hospitals: International Guide
Frequently Asked Questions About CIK Eligibility
My cancer has spread to multiple organs. Am I still eligible for CIK therapy?
Metastatic disease is not a contraindication to CIK therapy — many published RCTs specifically enrol stage IV patients. The key eligibility factors are performance status, immune reserve (ALC), and organ function — not the number of metastatic sites. For patients with good PS and adequate blood counts, CIK combined with systemic therapy (chemotherapy or targeted agents) represents the most evidence-based combination in the metastatic setting.
I have had multiple lines of chemotherapy. Will my immune cells still be good enough for CIK manufacturing?
Heavily pre-treated patients often have reduced lymphocyte counts due to cumulative myelosuppression. If your ALC is below 1.0 × 10⁹/L, CIK cell yield may be suboptimal. However, this depends on how long ago the last chemotherapy was given and how much immune recovery has occurred since. CancerFax requests a current FBC with differential as part of the pre-treatment assessment to determine whether manufacturing is feasible or whether a recovery interval is needed before collection.
I am 72 years old. Am I too old for CIK therapy?
Age alone is not a contraindication to CIK therapy. Published trials include patients in their 70s and 80s, and the favourable safety profile of CIK — with no CRS or ICANS risk — makes it one of the more appropriate advanced therapies for elderly patients. The relevant factors are performance status, organ function, and immune reserve — not chronological age. CancerFax assesses elderly patients based on these functional criteria rather than applying an age cut-off.
How does CancerFax assess my eligibility for CIK therapy?
Our clinical team reviews your pathology report, staging imaging, treatment history, current medications, most recent blood counts (FBC with differential, LFTs, renal function), and ECOG performance status documentation. We identify which CIK treatment context (adjuvant, combination, or standalone) best fits your case, and confirm with the specialist centre whether eligibility criteria are met before you commit to travel or treatment. This pre-travel eligibility review is provided at no charge.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If You Are a Good Candidate for CIK Therapy?
CancerFax reviews your complete medical records — cancer type, staging, performance status, prior treatments, and blood counts — and provides a clear assessment of whether CIK therapy is appropriate for your case, before any travel or treatment commitment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.